3 active not recruiting, 3 recruiting, 2 completed, 1 withdrawn. 5 Phase 1, 4 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 2, Active not recruiting 1, Completed 1, Withdrawn 1 |
| Phase 2 | 4 | Active not recruiting 2, Completed 1, Withdrawn 1 |
| Not applicable | 1 | Completed 1 |
Follow Primary Effusion Lymphoma: new trials by email Literature Review of Primary Effusion Lymphoma trials Research Report on Primary Effusion Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Recruiting | National Cancer Institute (NCI) | 15 | 2027-07-05 | 2026-10-28 |
| Study of SGR-1505 in Mature B-Cell Neoplasms SGR-1505 - Mature B-Cell Neoplasm, Non Hodgkin Lymphoma | Phase 1 | Recruiting | Schrödinger, Inc. | 98 | 2023-04-10 | 2026-02-13 |
| Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis Kaposi Sarcoma, KSHV Associated Multicentric Castleman Disease | Active not recruiting | National Cancer Institute (NCI) | 40 | 2021-02-04 | 2026-08-25 | |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Nivolumab, Varlilumab - ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2018-12-21 | 2026-10-26 |
| Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma Lenalidomide, Rituximab, Prednisone - Primary Effusion Lymphoma, B-Cell Neoplasm | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 17 | 2017-07-03 | 2026-10-20 |
| Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration - Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult T-Cell Leukemia/Lymphoma | Not applicable | Completed | Mayo Clinic | 29 | 2016-01-19 | 2019-11-15 |
| Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas Pomalidomide, Rituximab, Prednisone - Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease, Primary Effusion Lymphoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2014-08-15 | 2018-08-31 | |
| Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide - AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 107 | 2010-10-06 | 2023-11-21 |
| Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer HIV, Kaposi's Sarcoma | Recruiting | National Cancer Institute (NCI) | 1029 | 2000-12-06 | 2026-10-16 |
Lymphoma, Primary Effusion (9) · Lymphoma, Large B-Cell, Diffuse (4) · Plasmablastic Lymphoma (4) · Burkitt Lymphoma (3) · Lymphoma, Follicular (3) · Acquired Immunodeficiency Syndrome (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Mantle-Cell (2) · Multi-centric Castleman's Disease (2) · Sarcoma, Kaposi (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Bone Diseases, Metabolic (1)
Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphatic Diseases (9) · Lymphoproliferative Disorders (9) · Neoplasms by Histologic Type (9) · Lymphoma, Non-Hodgkin (8) · Neoplasms (8) · Lymphoma (7) · Lymphoma, B-Cell (7) · Infections (6) · DNA Virus Infections (5) · Herpesviridae Infections (5) · Virus Diseases (5) · Blood-Borne Infections (3)
Cyclophosphamide (4) · Doxorubicin (4) · Prednisone (4) · Rituximab (4) · Vincristine (4) · Etoposide (3) · CT-P10 (2) · deltacortene (2) · prednylidene (2) · Biopsy (1) · Bronchoscopy (1) · Disulfides (1) · Echocardiography (1) · Electrocardiography (1) · Endoscopy (1)
National Cancer Institute (NCI) (7) · Mayo Clinic (1) · Schrödinger, Inc. (1)
United States (8) · France (1) · Italy (1) · Moldova (1) · Poland (1) · Romania (1) · Spain (1) · Ukraine (1)
Frank G Basile, M.D. (1) · Juan C Ramos (1) · Ramya M Ramaswami, M.D. (1) · Ramya Ramaswami, MBBS, MPH (1) · Robert Yarchoan, M.D. (1) · Stefan K Barta (1) · Stephen M Ansell (1) · Thomas S Uldrick, M.D. (1) · Thomas Witzig (1)
PMID 32430507, PMID 37740179, PMID 38941593, PMID 41845569
UM1CA121947 (2), P30CA015083 (1), UM1CA186686 (1), UM1CA186709 (1)